Fluoguide AS
STO:FLUO
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
33.9
75.6
|
| Price Target |
|
We'll email you a reminder when the closing price reaches SEK.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Fluoguide AS
Common Shares Outstanding
Fluoguide AS
Common Shares Outstanding Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Common Shares Outstanding | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
F
|
Fluoguide AS
STO:FLUO
|
Common Shares Outstanding
kr12.2m
|
CAGR 3-Years
5%
|
CAGR 5-Years
20%
|
CAGR 10-Years
N/A
|
|
|
Genmab A/S
CSE:GMAB
|
Common Shares Outstanding
kr63.5m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
1%
|
CAGR 10-Years
1%
|
|
|
Zealand Pharma A/S
CSE:ZEAL
|
Common Shares Outstanding
kr70.6m
|
CAGR 3-Years
18%
|
CAGR 5-Years
15%
|
CAGR 10-Years
12%
|
|
|
Ascendis Pharma A/S
NASDAQ:ASND
|
Common Shares Outstanding
€60.6m
|
CAGR 3-Years
2%
|
CAGR 5-Years
5%
|
CAGR 10-Years
10%
|
|
|
B
|
Bavarian Nordic A/S
CSE:BAVA
|
Common Shares Outstanding
kr78.1m
|
CAGR 3-Years
7%
|
CAGR 5-Years
14%
|
CAGR 10-Years
12%
|
|
|
Bioporto A/S
CSE:BIOPOR
|
Common Shares Outstanding
kr429.7m
|
CAGR 3-Years
17%
|
CAGR 5-Years
15%
|
CAGR 10-Years
14%
|
|
Fluoguide AS
Glance View
FluoGuide A/S engages in the development of surgical solutions to reduce suffering for the patient and increase the likelihood of cure; as well as reducing costs for the health care system. The firm develops surgical solutions, which expected to reduce Cancer pain for the patient and increases the possibility of recovering as well as reducing costs for the health care system. The first product is the compound FG001, which lights up the cancer and its invasive growth into the surrounding tissue.
See Also
What is Fluoguide AS's Common Shares Outstanding?
Common Shares Outstanding
12.2m
DKK
Based on the financial report for Dec 31, 2023, Fluoguide AS's Common Shares Outstanding amounts to 12.2m DKK.
What is Fluoguide AS's Common Shares Outstanding growth rate?
Common Shares Outstanding CAGR 5Y
20%
Over the last year, the Common Shares Outstanding growth was 3%. The average annual Common Shares Outstanding growth rates for Fluoguide AS have been 5% over the past three years , 20% over the past five years .
You don't have any saved screeners yet
